Citadel Advisors’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$11.6M Buy
10,252,606
+49,277
+0.5% +$55.7K ﹤0.01% 1276
2025
Q1
$14.9M Buy
10,203,329
+4,854,233
+91% +$7.09M ﹤0.01% 1036
2024
Q4
$11.4M Buy
5,349,096
+309,502
+6% +$659K ﹤0.01% 1239
2024
Q3
$14.1M Buy
5,039,594
+2,593,091
+106% +$7.26M ﹤0.01% 1057
2024
Q2
$5.7M Sell
2,446,503
-666,722
-21% -$1.55M ﹤0.01% 1587
2024
Q1
$13.9M Sell
3,113,225
-940,001
-23% -$4.2M ﹤0.01% 1083
2023
Q4
$13M Sell
4,053,226
-62,404
-2% -$200K ﹤0.01% 1071
2023
Q3
$13M Sell
4,115,630
-624,711
-13% -$1.98M ﹤0.01% 993
2023
Q2
$23.6M Buy
4,740,341
+391,838
+9% +$1.95M ﹤0.01% 741
2023
Q1
$21.5M Buy
4,348,503
+3,808,199
+705% +$18.8M ﹤0.01% 816
2022
Q4
$3.4M Sell
540,304
-352,551
-39% -$2.22M ﹤0.01% 2138
2022
Q3
$9.64M Buy
892,855
+811,492
+997% +$8.76M ﹤0.01% 1313
2022
Q2
$927K Sell
81,363
-2,534,748
-97% -$28.9M ﹤0.01% 3492
2022
Q1
$23.8M Buy
2,616,111
+241,614
+10% +$2.2M ﹤0.01% 800
2021
Q4
$35.4M Buy
2,374,497
+2,064,988
+667% +$30.8M 0.01% 643
2021
Q3
$7.95M Sell
309,509
-101,301
-25% -$2.6M ﹤0.01% 1641
2021
Q2
$10.7M Buy
410,810
+379,323
+1,205% +$9.89M ﹤0.01% 1389
2021
Q1
$1.11M Sell
31,487
-272,366
-90% -$9.62M ﹤0.01% 3819
2020
Q4
$7.67M Buy
303,853
+240,364
+379% +$6.07M ﹤0.01% 1438
2020
Q3
$2.39M Sell
63,489
-33,851
-35% -$1.28M ﹤0.01% 2114
2020
Q2
$4.17M Buy
97,340
+42,054
+76% +$1.8M ﹤0.01% 1632
2020
Q1
$1.07M Sell
55,286
-960
-2% -$18.6K ﹤0.01% 2795
2019
Q4
$1.46M Sell
56,246
-295,648
-84% -$7.68M ﹤0.01% 2644
2019
Q3
$9.59M Sell
351,894
-91,683
-21% -$2.5M ﹤0.01% 1218
2019
Q2
$11.9M Sell
443,577
-220,926
-33% -$5.93M 0.01% 1086
2019
Q1
$19.2M Buy
664,503
+293,885
+79% +$8.5M 0.01% 769
2018
Q4
$9.98M Buy
+370,618
New +$9.98M 0.01% 999